We are ruthless in our evaluation of preclinical technologies, focusing on opportunities that have the potential to meet unmet medical needs and present a short path to value creation; we only pursue the best.
We follow a rigorous screening process to evaluate our investments in preclinical technologies.
We only pursue the technologies that meet our strict criteria, which includes a strong intellectual property position and commercial potential.
We only invest when we are certain the technologies meet our criteria.
We are focused on developing intellectual property and future revenue through patent filings and technology ownership.